The pharmaceutical company plans to submit the drug for regulatory approval in Japan by the end of this year. - AFP
TOKYO (Reuters): Japan's Shionogi & Co Ltd said on Wednesday (Sept 29) it plans to make at least 1 million doses of a new antiviral treatment for Covid-19 for domestic use by March 2022.
The company plans to submit the drug, a protease inhibitor known as S-217622, for regulatory approval in Japan by the end of this year, Chief Executive Isao Teshirogi said at a briefing.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
